Chandrashekar B S, Soumya Soragavi
Dr. Chandrashekar and Dr. Soragavi Soumya are with the Department of Dermatology and the CUTIS Academy of Cutaneous Sciences in Vijayanagar, Bangalore, India.
J Clin Aesthet Dermatol. 2022 Feb;15(2):18-22.
We sought to determine the efficacy and safety of a topical under-eye serum (Melalumin™; Menarini India Pvt Ltd.) in patients with periorbital hyperpigmentation (POH).
In this prospective, open-label single-arm study, 90 patients aged 18 to 55 years with Grade I to IV pigmentary POH, were given the under-eye serum for three months. Follow-up visits were scheduled at one, two and three months from baseline. Effectiveness was evaluated by two independent dermatologists using a skin colorimeter (Dermacatch) and dermoscopy (FotoFinder Systems, Inc., Medical Imaging Systems; Columbia, Maryland), as well as global photographs and patient-reported satisfaction ratings (excellent, very good, good, not satisfied). Adverse events were recorded. The colorimeter values were evaluated using the paired T test and the single-mean T test was used for dermoscopy and global clinical photographs.
Of the 90 patients included, 85 completed the study. Significant reductions in colorimeter values were noted in both melanin (from 708 to 621) and erythema (from 450 to 417) over three months (<0.05). Mean improvement in dermoscopic assessment was 48.41 percent; Most (n=73/85; 85.88%) patients achieved >25-percent improvement; over one-third (n=31/85; 36.47%) showed >50-percent improvement. Global photographs improved by 49.47 percent; most (n=75/85; 88.24%) patients showed >25-percent improvement, over one-third (n=38/85; 44.71%) showed >50-percent improvement. Patient satisfaction levels were high (Excellent: 16 [18.82%]; Very good: 38 [44.71%]); Good: 26 [30.59%]; Not satisfied: 5 [5.88%]). No adverse events were noted.
This study demonstrates safety and effectiveness of the studied under-eye serum in patients with pigmentary POH. In addition to clinical improvements noted by the investigators, significant improvements were also noted in colorimeter values, dermoscopy results, and global photographs. Patients exhibited high satisfaction levels with treatment outcomes. No safety concerns were noted.
我们旨在确定一种眼部下方外用精华液(Melalumin™;美纳里尼印度私人有限公司)对眶周色素沉着(POH)患者的疗效和安全性。
在这项前瞻性、开放标签单臂研究中,90名年龄在18至55岁、患有I至IV级色素性POH的患者使用该眼部下方精华液三个月。从基线开始,分别在1个月、2个月和3个月安排随访。由两名独立的皮肤科医生使用皮肤色度仪(Dermacatch)和皮肤镜(FotoFinder Systems公司,医学成像系统;马里兰州哥伦比亚)进行疗效评估,同时结合整体照片和患者报告的满意度评分(优秀、非常好、好、不满意)。记录不良事件。使用配对T检验评估色度仪值,使用单均值T检验评估皮肤镜和整体临床照片。
纳入的90名患者中,85名完成了研究。三个月内,黑色素(从708降至621)和红斑(从450降至417)的色度仪值均显著降低(<0.05)。皮肤镜评估的平均改善率为48.41%;大多数患者(n = 73/85;85.88%)改善超过25%;超过三分之一(n = 31/85;36.47%)改善超过50%。整体照片改善了49.47%;大多数患者(n = 75/85;88.24%)改善超过25%,超过三分之一(n = 38/85;44.71%)改善超过50%。患者满意度较高(优秀:16例[18.82%];非常好:38例[44.71%];好:26例[30.59%];不满意:5例[5.88%])。未观察到不良事件。
本研究证明了所研究的眼部下方精华液对色素性POH患者的安全性和有效性。除了研究人员观察到的临床改善外,色度仪值、皮肤镜检查结果和整体照片也有显著改善。患者对治疗结果表现出较高的满意度。未发现安全问题。